Summary: MAPS Public Benefit Corporation (MAPS PBC) Medical Director Alia Lilienstein, M.D., M.P.H., and Regulatory Affairs Manager Allison Coker, Ph.D., join the Lady Scientist Podcast to provide updates in the vast field of psychedelic research.
Dr. Lilienstein provides a thorough overview of MAPS PBC, including its current projects and recent findings, and outlines the primary distinctions between MAPS and MAPS PBC. Dr. Coker goes on to explain how the results of MAPS’ first Phase 3 trial of MDMA-assisted therapy for PTSD represent a “fundamental shift in the field of psychiatry.”
Originally appearing here.
